 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
9 News |  |
- Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2386;
For pts with RR cHL, long-term remission can be achieved following lower-intensity SLT with single-agent BV followed by ASCT, provided PET-normalization is achieved after single-agent BV. bMTV identifies which pts within this favorable group are likely to develop disease progression and therefore treatment strategies using bMTV to direct intensity of therapy should be explored.
- Alocrest (vinorelbine liposomal) / Spectrum, liposomal vinorelbine (TLC178) / Taiwan Liposome Company
In vivo efficacy and enhanced tumour accumulation of liposomal vinorelbine (TLC178) in human sarcoma xenograft mice model (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1918;
Therefore, TLC178 may have potential as a single or combination treatment for sarcomas with decreased dosage and/or frequency, reduced toxicity, and enhanced efficacy. Legal entity responsible for the study: Taiwan Liposome Company, Ltd.
- ||| Alocrest (vinorelbine liposomal) / Spectrum Pharma
Trial completion, Metastases: Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Sep 22, 2015
P1, N=67, Completed, Sponsor: Spectrum Pharmaceuticals, Inc
Legal entity responsible for the study: Taiwan Liposome Company, Ltd. Active, not recruiting --> Completed
- || Alocrest (vinorelbine liposomal) / Spectrum Pharma
Trial primary completion date, Metastases: Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Jun 11, 2015
P1, N=67, Active, not recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2015